Baxter launches next-gen Floseal, Tisseel hemostatic agents

Monday, April 3, 2017

Source: Mass Device

Baxter (NYSE:BAX) today launched next-gen versions of its Floseal and Tisseel hemostatic products, with improved applicability and designs.

The Deerfield, Ill.-based company launched the Floseal full sterile preparation system, designed to be prepared by a single person with fewer steps than previous versions. The newly launched hemostatic has the same clearances as prior versions, the company added.

“Baxter is committed to introducing innovative products designed to improve patient safety and ease of use. We are excited to bring customer-inspired enhancements to our leading hemostat and sealant portfolio that surgeons rely on for safe and effective solutions to address intraoperative bleeding,” Baxter advanced surgery biz prez Wil Boren said in a press release.

Baxter also launched a new version of its Tisseel hemostatic, touting an improved applicator designed to snap and lock onto the syringe for improved attachment.

Last month, Baxter touted the publication of 2 health economic analyses of its Floseal hemostatic matrix, touting it as a cost-saving solution for hospitals to control bleeding during cardiac and spinal surgeries.

Data in the studies came from previously published retrospective studies of a large US hospital billing database, according to Baxter. Results were published recently in the Journal of Medical Economics.

View All News »